Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors | BMC Cancer | Full Text

Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors | BMC Cancer | Full Text

Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors

Colorectal cancer (CRC) is the second most common cause of cancer-related mortality worldwide with one in every five patients diagnosed with metastatic CRC (mCRC). In mCRC cases, the 5-year survival rate remai...

Authors:Susan A. Kennedy, Maria E. Morrissey, Margaret R. Dunne, Fiona O’Connell, Clare T. Butler, Mary-Clare Cathcart, Amy M. Buckley, Brian J. Mehigan, John O. Larkin, Paul McCormick, Breandán N. Kennedy and Jacintha O’Sullivan

Citation:BMC Cancer 2020 20:952

Content type:Research article

 

Published on: 2 October 2020

• ViewFull Text
 
• ViewPDF